Allakos is a clinical stage biotechnology company. Co. is developing AK002, its wholly owned monoclonal antibody, for the treatment of various mast cell and eosinophil related diseases. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. Inappropriately activated mast cells and eosinophils have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a number of severe diseases. The ALLK stock yearly return is shown above.
The yearly return on the ALLK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALLK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|